Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 15, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will participate in a fireside chat at the 2017 RBC Capital Markets Global Healthcare Conference on Wednesday, February 22, 2017 at 9:30 a.m. ET.

A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-2017-rbc-capital-markets-global-healthcare-conference-300405052.html

SOURCE Blueprint Medicines Corporation

Copyright 2017 PR Newswire